Keyword :   immune checkpoint inhibitors

Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
Т. 14, №4 (56)
KEYNOTE-006 study: results of 10-year follow-up of pembrolizumab versus ipilimumab in advanced melanoma
Т. 14, №4 (56)
Management of immunotherapy toxicity: European Society for Medical Oncology (ESMO) clinical guidelines for diagnosis, treatment and patient follow-up
Т. 14, №3 (55)
A case of superficially spreading melanoma associated with an intradermal nevus
Authors: Voloshynovych M. Boichuk T. Matkovska N. Tkach V.... Т. 14, №1 (53)
Expanding the role of immuno-oncology treatment in the management of patients with melanoma or triple-negative breast cancer
Т. 13, №4 (52)
A clinical case of treating of a patient with melanoma using checkpoint inhibitor pembolizumab (anti-PD-1 monoclonal antibody)
Author:Kosinova V.G. №4(28) 2017
Innovative breakthrough in cancer immunotherapy: pembrolizumab opportunities
Author:Maltsev D.V. №4(24) 2016